In a preliminary internal review , the orally administered , broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell cultures in laboratory testing .
In this analysis , Vicromax(tm) was added to a tissue culture assay for SARS-CO-2 coronavirus ( the causative agent for COVID-19 ) and an anti-viral effect was observed , which led to a reduction of over 90% of infectious viruses .
The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials .
The product candidate already completed Phase I and three Phase II trials in other indications , and underwent extensive animal testing and human clinical experience .
The Company expects that Vicromax(tm) could be used alone or in a combination with other anti-viral agents or immune modulators .
" Stopping the COVID-19 pandemic and preventing similar viral threats in the future must be the number-one priority of all of us in the healthcare community , " said Kenneth L .
Londoner , Chairman and CEO of BioSig Technologies , Inc .
" This very promising anti-viral is the result of tireless efforts by an accomplished group of pharmaceutical industry veterans , and @ @ @ @ @ @ @ @ @ @ gets tested and brought to market as soon as possible .
"  The Company intends to develop Vicromax(tm) and take it through clinical trials under a new NeuroClear subsidiary , ViralClear Pharmaceuticals , Inc .
The Company appointed Mr .
Nick Spring as Chief Executive Officer of ViralClear and Mr .
Steve King as Chief Operating Officer .
Spring is a seasoned global executive and entrepreneur with experience spanning both human and animal health .
During his extensive career at Merck &amp; Co .
, he led the worldwide franchise for live viral human vaccines as well as the strategic team that crafted the US launch plan for the HPV vaccine , Gardasil ? , which became a billion-dollar franchise .
Most recently , Mr .
Spring was Founder and CEO of Humanitas , a biotechnology and life sciences consulting firm that advises blue-chip global companies .
Previously , he served as President and CEO of a medical device company , Reliefband Technologies , and as Founder and CEO of Topaz Pharmaceuticals Inc , where he raised $35 million in private investment and took the company from concept to FDA approval @ @ @ @ @ @ @ @ @ @ to Sanofi .
Earlier in his Merck career , Mr .
Spring helped build the Ivermectin family of endectocides into a billion-dollar global franchise and manage the start-up of Merial , a Merck/Sanofi animal health joint venture .
While at Merial , Mr .
Spring was part of the strategic leadership planning team that laid the foundations for Heartgard ? and the blockbuster Frontline ? brand .
King is an experienced pharmaceutical executive with proven skills in business development , licensing , and small-molecule drug development and commercialization .
Most recently , he served as President at 21159 Pharma , a strategic consulting and business development company .
Previously he was Senior Vice President at Pii ( Pharmaceutics International Inc ) , building the contract development and manufacturing organization ( CDMO ) in the US and the UK .
Earlier in his career , Mr .
King worked for Janssen Pharmaceuticals and managed international business development for UK-based R .
Scherer Corporation ( Catalent ) , which specializes in the development and supply of pharmaceutical products including softgel products .
He earned his Pharmacy degree from the London School of Pharmacy .
@ @ @ @ @ @ @ @ @ @ commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals ( www .
biosig .
The Company 's first product , PURE EP(tm) System is a computerized system intended for acquiring , digitizing , amplifying , filtering , measuring and calculating , displaying , recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology ( EP ) procedures in an EP laboratory .
About NeuroClear TechnologiesNeuroClear Technologies , a majority-owned BioSig subsidiary , is a medical technology company focused on electroneurogram recordings .
The Company aims to address some of the biggest challenges of bioelectronic medicine devices through targeted stimulation and feedback loops for optimal therapy delivery .
Forward-looking Statements This press release contains " forward-looking statements .
" Such statements may be preceded by the words " intends , " " may , " " will , " " plans , " " expects , " " anticipates , " " projects , " " predicts , " " estimates , " " aims , " " believes , " " hopes , @ @ @ @ @ @ @ @ @ @ statements are not guarantees of future performance , are based on certain assumptions and are subject to various known and unknown risks and uncertainties , many of which are beyond the Company 's control , and can not be predicted or quantified and consequently , actual results may differ materially from those expressed or implied by such forward-looking statements .
Such risks and uncertainties include , without limitation , risks and uncertainties associated with ( i ) our inability to manufacture our products and product candidates on a commercial scale on our own , or in collaboration with third parties ; ( ii ) difficulties in obtaining financing on commercially reasonable terms ; ( iii ) changes in the size and nature of our competition ; ( iv ) loss of one or more key executives or scientists ; and ( v ) difficulties in securing regulatory approval to market our products and product candidates .
More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company 's filings with the Securities and Exchange Commission ( SEC @ @ @ @ @ @ @ @ @ @ 10-K and its Quarterly Reports on Form 10-Q .
Investors and security holders are urged to read these documents free of charge on the SEC 's website at http : //www .
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information , future events or otherwise .
In This Story  Sign up for our newsletter to get the latest on the transformative forces shaping the global economy , delivered every Thursday .
Email Address*  Location*  Please opt-in to receive news and information about Nasdaq 's services .
If you do not opt-in you will not receive any emails from Nasdaq .
Yes ! I would like to receive Nasdaq communications related to Products , Industry News and Events .
can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy .
